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Abbreviations: MPER, membrane-proximal external region; TMD, transmembrane domain; 
Env, HIV-1 envelope glycoprotein; molecular dynamics (MD); bNAb, broadly neutralizing 
antibody; CDR-H3, complementarity-determining region three of the heavy chain; HC, heavy 
chain; WT, wild-type; pBPA, p-benzoylphenylalanine; DMPC, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine; DHPC, 1,2-dihexanoyl-sn-glycero-3-phosphocholine; Chol, cholesterol; 
POPC, 1-palmitoyl-2- oleoyl-sn-glycero-3-phosphocholine; PA, L-α-phosphatidic acid, 
POPA, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate; Rho-PE, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl); CD, circular dichroism; HFIP, 
1,1,1,3,3,3-hexafluoro-2-propanol; NP, number of atomic interaction pairs;  MAb4E10, 
monoclonal antibody 4E10; HRP, horseradish peroxidase.  
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Abstract 
The 10E8 antibody achieves near-pan neutralization of HIV-1 by targeting the remarkably 
conserved gp41 membrane-proximal external region (MPER) and the connected 
transmembrane domain (TMD) of the HIV-1 envelope glycoprotein (Env). Thus, recreating 
the structure that generates 10E8-like antibodies is a major goal of the rational design of 
anti-HIV vaccines. Unfortunately, high-resolution information of this segment in the native 
Env is lacking, limiting our understanding of the behavior of the crucial 10E8 epitope 
residues. 
In this report, two sequences, namely, MPER-TMD1 (gp41 residues 671-700) and MPER-
TMD2 (gp41 residues 671-709) were compared both experimentally and computationally, to 
assess the TMD as a potential membrane integral scaffold for the 10E8 epitope. These 
sequences were selected to represent a minimal (MPER-TMD1) or full-length (MPER-
TMD2) TMD membrane anchor according to mutagenesis results reported by Yue et al. 
(2009) J. Virol. 83, 11588. Immunochemical assays revealed that MPER-TMD1, but not 
MPER-TMD2, effectively exposed the MPER C-terminal stretch, harboring the 10E8 epitope 
on the surface of phospholipid bilayers containing a cholesterol concentration equivalent to 
that of the viral envelope. Molecular dynamics simulations, using the recently resolved TMD 
trimer structure combined with the MPER in a cholesterol-enriched model membrane 
confirmed these results and provided an atomistic mechanism of epitope exposure which 
revealed that TMD truncation at position A700 combined with N-terminal addition of lysine 
residues positively impacts epitope exposure. Overall, these results provide crucial insights 
into the design of effective MPER-TMD derived immunogens. 
Key words: Molecular dynamics simulation; transmembrane domain; antigenicity; vaccine 
development; HIV-1. 
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1. Introduction 
The HIV-1 envelope glycoprotein (Env) is a class I viral fusion glycoprotein that initiates the 
infection cycle and the only protein on the viral particle accessible to the immune system. 
Since the publication in 2013 of the high-resolution cryo-EM [1] and x-ray [2] structures of 
the clade A BG505 strain SOSIP construct, a stabilized soluble prefusion Env trimer cleaved 
at position D664, several other native-like structures from the same [3] and other clades [4, 
5] have been reported and have provided detailed information on the architecture of the 
native gp41 ectodomain (for a comprehensive review of the available Env structures, see 
[6]). By comparison, less is known on the structure-function relationships regarding the 
MPER and TMD sequences after position D664. Besides its structural role in anchoring the 
Env complex to the viral membrane [7, 8], the MPER-TMD region is required for cell-cell 
fusion, viral infectivity and immunosuppression [9-18]. Moreover, the highly conserved 
MPER sequence constitutes a vulnerability site on the Env complex targeted by broadly 
neutralizing antibodies (bnAbs) [19-22]. Specifically, antibodies directed against the MPER 
C-terminal helix, such as 4E10 or 10E8, display near pan-neutralization activity in standard 
panels of HIV strains and isolates [23, 24]. Since 10E8 is a more potent antibody that lacks 
polyreactivity, ongoing immunogen-design strategies target this antibody [19, 22, 25].  
In this regard, previous studies suggested that the neutralization-competent structure of the 
MPER might also implicate part of the native TMD sequence [13, 26-29]. Accordingly, 4E10 
and 10E8 bnAbs bound to MPER expressed on the surface of the plasma membrane with 
significantly higher affinity when tethered to it via the TMD of HIV-1 gp41, rather than via the 
platelet-derived growth factor receptor TMD [26]. Supporting the involvement of the TMD in 
MPER antigenicity, we have recently reported NMR [28] and x-ray structural data [30] 
indicating that the C-terminal half of the MPER and the N-terminal half of the TMD (MPER-
N-TMD) arrange into a continuous helix spanning residues 673 to 690. This observation was 
reinforced by the publication of a NMR structure of a HIV-1 clade D TMD trimer (isolate 
92UG024.2, residues 677-716, HXB2 numbering) in DMPC:DHPC (1:2, mol:mol) bicelles 
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[13]. Together, these results oppose the long-standing hypothesis that the helix bends at the 
MPER-TMD connection (residue K683) to allow TMD insertion into the membrane in an 
orientation perpendicular to the bilayer plane [31, 32]. In accordance with the experimental 
evidence, we hypothesized that the unbent MPER-N-TMD helix might function as a scaffold 
to increase the affinity of anti-MPER antibodies at membrane surfaces [28] and found that 
indeed, the complete 10E8 epitope includes TMD residues beyond K683 [30].  
In this work, we analyze the effect of elongating the continuous MPER-N-TMD -helix 
towards the TMD C-terminus on the exposure of the 10E8 MPER epitope at membrane 
surfaces (Fig. 1). To this end, immunochemical assays and molecular dynamics (MD) 
simulations have been employed to analyze the potential of MPER-TMD derived sequences 
of different lengths to scaffold the 10E8 epitope when incorporated into liposomal vaccines 
with a cholesterol concentration that matches that of the viral envelope [33]. Moreover, the 
effect on epitope exposure of N- and/or C-terminal positive charge addition is analyzed. Our 
findings have the potential to aid the development of new vaccine formulations that 
effectively elicit the production of 10E8-like anti-MPER antibodies. 
 
 
2. Materials and Methods 
2.1 Materials 
Synthetic peptides derived from the gp41 MPER-TMD, KKK-
671NWFDITNWLWYIKLFIMIVGGLVGLRIVFA700-KKKK (MPER-TMD1) and 
671NWFDITNWLWYIKLFIMIVGGLVGLRIVFAVLSVVNRVR709 (MPER-TMD2) were produced 
by solid-phase synthesis using Fmoc chemistry as C-terminal carboxamides and purified by 
HPLC. 1-palmitoyl-2-oleoyl-sn-glycero-3-phophocholine (POPC), L-α-phosphatidic acid 
(Egg, Chicken) (PA), cholesterol (Chol), and 1,2-dioleoyl-sn-glycero-3-
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phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rho-PE) were purchased from 
Avanti Polar Lipids. Goat anti-Human IgG (Fab specific) was obtained from Sigma-Aldrich, 
rabbit anti-Human IgG-HRP and mouse anti-goat IgG-HRP from Santa Cruz Biotechnology. 
Monoclonal antibody 4E10 (MAb4E10) was kindly donated by D. Katinger (Polynum Inc., 
Vienna, Austria). 4E10 and 10E8 wild type Fabs, their non-functional mutant versions and 
their Trp100bHCpBPA substituted versions were produced as previously described [27, 30].  
2.2 Circular Dichroism 
Circular dichroism (CD) measurements were obtained from a thermally controlled Jasco J-
810 circular dichroism spectropolarimeter calibrated routinely with (1S)-(+)-10-
camphorsulfonic acid, ammonium salt. Samples consisted of lyophilized synthetic peptides 
dissolved at concentrations of 0.03 mM in 2 mM Hepes (pH, 7.4) buffer containing 25 % (v/v) 
of the low-polarity organic solvent 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). Spectra were 
measured in a 1 mm path-length quartz cell initially equilibrated at 25 ºC. Data were taken 
with a band-width of 1 nm at 100 nm/min speed, and the results of 20 scans were averaged. 
2.3 Peptide reconstitution into liposomes 
To ensure proper incorporation of the peptides into the vesicles, lipids and peptides (MPER-
TMD1 and MPER-TMD2) were mixed in organic solvent prior to the production of the 
liposomes. Briefly, POPC, Chol and PA were dissolved in chloroform:methanol 1:2 (vol:vol) 
at 10:11:1 (mol:mol) ratio and were mixed with MPER-TMD1 or 2 (dissolved in % 100 
ethanol) to achieve a peptide-to-lipid molar ratio of 1:50. The mixture was dried under a N2 
stream and traces of organic solvents were removed by 2 h vacuum pumping. 
Subsequently, the dried lipid films were subjected to 2 h of gentle hydration with H2O using a 
N2 gas bubbler to facilitate the subsequent dispersion of the dried lipid-peptide film in PBS 
aqueous buffer. Next, the multilamelar vesicles were bath sonicated (1 h, 55 ºC) and 
subjected to 15 freeze and thaw cycles to obtain unilamelar vesicles. Chol concentration of 
liposome suspensions was determined by the cholesterol oxidase/peroxidase method 
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(BioSystems, Barcelona, Spain), and found to be within the experimental error. 
2.4 Liposome flotation assay 
Following the method described by Yethon et al. [34], vesicle flotation experiments in sucrose 
gradients were performed to assess the association of 4E10 and 10E8 Fabs or their mutant 
counterparts to their epitopes presented by the MPER-TMD1 or MPER-TMD2 scaffolds in 
cholesterol-enriched membranes. In brief, 200 μL of a sample containing rhodamine-labeled 
liposomes (1.5 mM lipid concentration, 0.5 mol % Rho-PE)) and peptide (30 μM peptide; 1:50 
peptide-to-lipid molar ratio) was incubated with Fabs for 15 min at RT under constant stirring 
(800 rpm). 100 μL of the sample was adjusted to a sucrose concentration of 1.4 M in a final 
volume of 300 μL, and subsequently overlaid with 400 μL- and 300 μL-layers of 0.8 M and 
0.5 M sucrose, respectively. The gradient was centrifuged at 436,000  g for 3 h at 4 ºC in a 
TLA 120.2 rotor (Beckman Coulter). After centrifugation, four 250 μL-fractions were collected. 
Material adhered to tubes was collected into a 5th fraction by washing with 250 μL of hot 
(100 ºC) 1 % (w/v) SDS. The presence of PER-TMD truncated peptides and Fabs in the 
different fractions and in the original sample (input) was revealed by Western Blot analysis 
after Tris-Tricine SDS-PAGE separation. MAb4E10 (0.05 µg/ml) and rabbit anti-human-IgG-
HRP, and goat anti-Human IgG (Fab specific) and mouse anti-goat IgG-HRP antibody pairs 
were used to reveal peptides and Fabs, respectively. The presence of liposomes in the 
different fractions was determined after measuring the fluorescence emission of the Rho-PE 
probe [12].  
2.5 Photo-cross-linking assay 
For the photo-cross-linking experiments, samples containing 1.5 μM Fab bearing the 10E8 
or 4E10 W100bHCpBPA substitution and 30 μM of peptides MPER-TMD1 or MPER-TMD2 in 
solution (PBS) or reconstituted into membranes (1.5 mM lipid) were incubated for 15 min at 
RT and irradiated afterwards with UV light at 365 nm for 20 min at 4 °C, using a UVP B-
100AP lamp. Finally, Fab heavy-chain-peptide adducts were separated by 15 % Tris-Glicine 
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SDS-PAGE and stained with Coomassie blue.  
2.6 Molecular Dynamics Simulations 
The atomic structures of the HIV-1 gp41 TMD trimer (PDB ID: 5JYN) [13] and the MPER-N-
TMD helix (PDB ID: 5GHW) [30] were superposed to create models of peptide trimers 
representing the MPER-TMD region with or without C-terminal truncations, and with or 
without N- and/or C-terminal lysine residues. Residues 671 to 689 were extracted from 
5GHW, with residues from 690 onwards obtained from 5JYN, to ensure agreement between 
the peptide sequences used experimentally and computationally. 
The N-termini of the peptides were modeled in a charged state whilst the C-termini were 
amidated. Default protonation states were used for ionizable residues.  Water molecules 
were manually added to the region surrounding the protonated R696, in keeping with the 
presence of structured water molecules noted by Dev et al. [13]. Peptide assemblies MPER-
TMD1 (no lysines, N-terminal lysines, C-terminal lysines, and N- and C- terminal lysines), 
and MPER-TMD2 (no lysines), were inserted into model membranes, containing POPC, 
POPA and cholesterol molecules in a 10:11:1 ratio, using the CHARMM-GUI Membrane 
Builder [35-37]. For this purpose, the replacement method was utilized. In this approach, 
pseudo atoms representing lipids are distributed around the protein, and replaced with 
molecules randomly selected from the associated lipid molecule library [35]. The system was 
solvated with approximately ~30,000 water molecules, with added NaCl to mimic to the 150 
mM experimental concentration and achieve neutralization. NAMD2.9 was employed to 
perform MD simulations [38]. The CHARMM36 force field was used to describe the peptide 
and lipids [39], the TIP3P model for water [40], and standard parameters were used for ions 
[41]. The Particle Mesh Ewald method was used for the treatment of periodic electrostatic 
interactions, with an upper threshold of 1 Å for grid spacing [42]. Electrostatic and van der 
Waals forces were calculated every time step. A cut-off distance of 12 Å was used for van 
der Waals forces. A switching distance of 10 Å was chosen to smoothly truncate the non-
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bonded interactions. Only atoms in a Verlet pair list with a cut-off distance of 14 Å 
(reassigned every 20 steps) were considered [43]. The SETTLE algorithm was used to 
constrain all bonds involving hydrogen atoms to allow the use of a 2 fs time step throughout 
the simulation [44]. The Nose-Hoover-Langevin piston method was employed to control the 
pressure with a 200 fs period, 50 fs damping constant and a desired value of 1 atmosphere 
[45, 46]. The system was coupled to a Langevin thermostat to sustain a temperature of 298 
K throughout. Systems were minimized for 1000 steps, and then subject to 4 ns of 
constrained dynamics to equilibrate. Four equilibration steps of 1 ns were performed, with 
restraints (force constant: 1 kcal/mol) imposed on different elements of the system to ensure 
gradual relaxation of the system; 1) protein atoms, lipid head groups, and water molecules 
within the trimer pore and in contact with R696 are restrained, in order to relax lipid tails and 
water molecules in the vicinity of the lipid headgroups; 2) protein atoms and water molecules 
within the trimer pore and in contact with R696 are restrained, so lipid molecules can adjust 
to the protein surface; 3) only protein atoms are restrained, to ensure internal water 
molecules, and those in contact with R696 residues, occupy the most energetically 
unfavourable positions; 4) protein backbone atoms are restrained, to allow optimisation of 
side-chain dynamics. Unconstrained dynamics was then performed for 200 ns. Analysis was 
performed using in-house TCL scripts for VMD [47]. 
 
3. Results 
3.1 Design of the MPER-TMD1 and MPER-TMD2 peptide scaffolds 
Figure 1A describes the two sequences derived from the MPER-TMD region that were 
designed to upgrade our previous vaccines based on the MPER-N-TMD sequence (termed 
CpreTM in our recent work) [28]. To that end, these sequences included different sections of 
the native TMD sequence, due to the previously reported positive effect in 4E10 and 10E8 
antibody binding to their epitopes [30, 48]. The MPER-TMD1 sequence encompasses Env 
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residues 671NWFDITNWLWYIKLFIMIVGGLVGLRIVFA700 (sequence numbering derived from 
the prototypic HXBc2 isolate) and embodies the unbent MPER-N-TMD helix (residues 673 to 
690, underlined) [28, 30] including the complete 10E8 epitope sequence (critical residues in 
bold) [24, 30, 49], which has been elongated to include part of the C-terminus of the TMD (in 
italics). The TMD portion in this sequence has been truncated at position A700 according to 
mutagenesis results reported by Yue et al. [9]. This mutant was found to represent a minimal 
TMD anchor, which allowed efficient transport of Env to the plasma membrane, and wild-
type levels of cell-cell fusion [9]. Finally, three and four lysine residues were added to this 
sequence at the N- and C-termini, respectively, to match the hydrophobicity of our previously 
reported CpreTM sequence [28]. The MPER-TMD2 sequence (Env residues, 
671NWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSLVNRVR709) bears the 10E8 epitope 
(critical residues in bold), the MPER-N-TMD helix sequence (underlined) and the sequence 
assumed to span the full TMD (in italics) [50], which contains the minimal number of amino 
acids required for WT-like incorporation of Env and some degree of infectivity [9].  
3.2 Experimental assessment of the antigenicity of MPER-TMD scaffolds 
3.2.1 Secondary structure  
Following synthesis, the secondary structures of MPER-TMD1 and MPER-TMD2 peptides 
were compared by circular dichroism in the low-polarity organic solvent HFIP that roughly 
mimics the membrane environment. As shown in figure 1B, the synthetic peptides adopted 
similar levels of -helical conformation, as expected from previous structural studies [13, 28], 
underpinning their further comparison as synthetic surrogates of the MPER-TM domain. 
3.2.2 Incorporation into membranes and antigenicity  
Next, we tested experimentally the capacity of the synthetic peptides to incorporate into 
cholesterol-enriched bilayers and expose the 10E8 MPER epitope at membrane surfaces. In 
those assays, MPER-TMD1 and MPER-TMD2 (Figs. 2A and 2B, respectively, 10 kDa 
panels) mostly co-floated with lipid vesicles (rhodamine emission spectra) upon physical 
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separation of bound and unbound species by ultracentrifugation in a sucrose gradient. The 
absence of peptide in the SDS and 1st fractions (non-floated fractions) further confirmed that 
both peptides were effectively incorporated into vesicles containing 50 mole % cholesterol. 
The appropriate display (antigenicity) of the 10E8 bnAb epitope in the MPER-TMD peptides 
reconstituted into membranes was subsequently assayed (Fig. 2). To this end, the binding 
capacity of the reconstituted MPER-TMD petides to a functional (neutralizing) wild type 10E8 
Fab (Fig. 2, left panels) and to a non-functional (non-neutralizing) mutant Fab (Fig. 2, right 
panels) was compared. The 10E8 mutant Fab, termed 10E8 W100bD, was obtained by 
decreasing the hydrophobicity of the CDR-H3 loop after substitution of the critical tryptophan 
residue 100b of the CDR-H3 apex with Asp, a mutation that abrogates neutralization and 
binding to the epitopes in a membrane milieu [30]. Therefore, it comprises a valuable tool to 
discriminate functional and non-functional binding to the liposome-peptide formulations 
proposed as immunogens. The 10E8 wild type Fab, but not the W100bD mutant, effectively 
recognized the MPER-TMD1 peptide in the membrane, demonstrated by the 25 kDa bands 
corresponding to the Fab, co-floating with the liposomes bearing the peptide (Fig. 2A, left 
panel). This result reveals the capacity of MPER-TMD1 reconstituted into cholesterol-
enriched vesicles to effectively expose the epitope of the 10E8 bnAb following a 
neutralization-competent pattern. In contrast, both wild type and mutant Fabs were 
recovered from the non-floated fractions when the epitope was presented by the MPER-
TMD2 peptide in the surface of the liposomes (Fig. 2B) or when the epitope was absent (Fig. 
2C). Overall, these results are consistent with the correct exposure of the epitope in the 
MPER-TMD1 scaffold when reconstituted into cholesterol-enriched liposomes and reveal its 
potential as an immunogen to elicit 10E8-like anti-MPER antibodies.  
To determine whether the observed difference in antigenicity between the two MPER-TMD 
scaffolds was specific to the 10E8 antibody or could be reproduced with other anti-MPER 
antibodies, the same experiment was performed with Fab 4E10, whose epitope maps to the 
same region [24, 51]. As shown in figure S1, wild type 4E10 Fab recognized and bound to 
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MPER-TMD1 reconstituted into liposomes (Fig. S1A, left panel), but was recovered from the 
non-floating fractions either when the epitope was presented by the MPER-TMD2 scaffold 
(Fig. S1B, left panel) or in the absence of the epitope (Fig. S1C, left panel). Following the 
same strategy used with 10E8, a non-functional (non-neutralizing) 4E10 mutant Fab was 
also assayed to determine the relevance of the MPER-TMD1 scaffold as immunogen. This 
mutant, termed 4E10 Δloop, has an intact paratope while the tip of the CDR-H3 loop is 
ablated. Preservation of this loop is required for neutralization [27] but its deletion has a 
negligible effect on Fab binding to the epitope in solution, displaying near wild type affinity 
[49]. Similarly to 10E8 W100bD and in contrast to 10E8 or 4E10 wild type Fabs, 4E10 Δloop 
binding to MPER-TMD scaffolds reconstituted in a membrane was barely detected (Fig. S1, 
right panels). Together, these data suggest that the C-terminal MPER epitope targeted by 
these bnAbs is not properly exposed in the MPER-TMD2 scaffold. 
Binding assays were next complemented with photo-cross-linking experiments. This 
approach allows scoring effective engagement of the epitope peptide with the antibody in an 
intact system [48] and serves to rule out the possibility that the antibodies bound to MPER-
TMD2, but would dissociate during the ultracentrifugation protocol (Fig. 3). To carry out the 
experiment, the UV-sensitive unnatural amino acid p-benzoylphenylalanine (pBPA) [52, 53], 
was genetically encoded at position Trp100b of the 10E8 Fab heavy chain (HC) CDR-H3 tip. 
Following incubation of the modified Fab with either MPER-TMD1 or MPER-TMD2 in 
solution or reconstituted into membranes, the samples were subjected to UV light, and the 
formation of covalent adducts analyzed by SDS-PAGE. As expected, an additional band 
corresponding to cross-linked peptide and Fab 10E8 HC was observed in MPER-TMD1 
containing samples, both in solution and in liposomes, but not in samples containing MPER-
TMD2 in liposomes, consistent with the flotation assay. However, a shift in the gel was also 
observed in MPER-TMD2 samples devoid of a lipid membrane, indicating that correct 
exposure of the epitope is reliant on its environment, with membrane insertion hindering 
recognition of the epitope by the anti-MPER antibody. The new band was absent in all cases 
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before irradiation (UV- lines) and in the absence of the epitope, demonstrating that UV-
mediated cross-linking specifically causes the appearance of this band.  
Flotation and photo-cross-linking experiments also revealed that MPER-TMD1 migrated on 
tricine-SDS-PAGE with an apparent molecular weight of 10 kDa (theoretical MW of 4.5 kDa 
for MPER-TMD1) revealing the potential of this peptide to form stable dimers even in the 
harsh conditions of the experiments (5 min at 100 ºC and 1 % SDS). On the contrary, 
MPER-TMD2 migrated as two bands, compatible with dimers and trimers, suggesting 
formation of stable higher-order oligomers in cholesterol-enriched membranes. This 
differential behavior might have implications in the effective exposure of the MPER epitope 
at the membrane surface.  
3.3 Molecular Dynamic Simulations of MPER-TMD derived peptide scaffolds 
3.3.1 Construction of the models 
To understand the molecular mechanism underlying the above experimental observations, 
molecular dynamics (MD) simulations of the MPER-TMD1 and MPER-TMD2 peptides 
inserted into HIV-1-like cholesterol-enriched membranes were performed. The starting 
models (Fig. 4A) were constructed by superposition of the MPER-N-TMD structure (PDB ID:  
5GHW), residues 671-689, with residues 690-700 or 690-709 of the individual helices of the 
recently resolved TMD trimer (PDB ID: 5JYN), to form MPER-TMD1 and MPER-TMD2, 
respectively. As described earlier, synthetic peptides and lipids were mixed in organic phase 
to produce liposomal vaccines; peptides were not added to preformed liposomes from the 
aqueous phase. Moreover, the free energy change of transferring residues from 671 to 693 
from interface to octanol is negative [54] and residues downstream K683 have a 
hydrophobicity profile compatible with that of a membrane-buried sequence [55]. Thus, 
rather than laying on the bilayer surface parallel to the plane of the membrane, the trimers 
were inserted into the membrane assuming in both cases a disposition parallel to the bilayer 
normal (Fig. 4A). MD simulations were performed for 200 ns (Fig. 4B), with the initial 100 ns 
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period considered an equilibration period. Therefore, only the final 100 ns of the simulations 
is considered in the analysis presented hereafter. 
3.3.2 Overall stability of the models  
Firstly, the root-mean-square deviation (RMSD) of the C atoms from the initial structure 
was monitored over time to assess the stability of the epitope region in the MPER-TMD 
derived constructs (Fig. 5A). The RMSD of MPER-TMD1 (4.4 ± 0.3 Å) is significantly higher 
than that of MPER-TMD2 (2.3 ± 0.2 Å), suggesting the assemblies adopt different 
configurations, with the latter resembling the initial construct most closely, based upon the 
NMR structure of the HIV-1 TMD and demonstrated by the calculated number of interaction 
pairs between adjacent helices (Fig. 5B) in each assembly. 300 to 450 atomic interaction 
pairs are present between adjacent helical pairs (CA > BC > AB) in MPER-TMD2, 
suggesting a near-symmetrical trimer assembly. An interaction number of this magnitude is 
only observed for the AC helix pair in MPER-TMD1, with the remaining number of pairwise 
interactions considerably reduced, to 237 and 118 between helices AB and BC, respectively. 
These observations suggest that the MPER-TMD1 trimer is unstable and might dissociate in 
a cholesterol-enriched bilayer, in agreement with earlier experimental results establishing 
the existence of MPER-TMD1 dimers (Fig. 2). 
Moreover, inspection of the transmembrane helix tilt angle () for residues 671-690, relative 
to the bilayer normal, showed noticeable differences between the trimers (Fig. 5C). At the 
beginning of the simulation (0 ns) helices A, B and C displayed tilt angles of 15.2°, 18.4° and 
25.3°, respectively. In the last 100 ns of the simulation, helices A and B of the MPER-TMD2 
trimer occupy a similar range, between 8-14º relative to the bilayer normal, whereas helix C 
fluctuates between 17-20°. Therefore, all of them display an increased verticality as 
compared to the initial model. In contrast, helices B and C of MPER-TMD1 display tilt angles 
of ca. 16° and 28°, equivalent to the initial model, whilst the tilt angle of helix A increases to 
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ca. 24º. This result suggests that the assembly of the transmembrane trimer is noticeably 
perturbed.  
3.3.3 Specific molecular interactions that define the observed conformations  
To gain further insight at the molecular level into the interactions that contribute to the 
stabilization of the constructs in the simulations, we next analyzed the contacts between 
specific amino acids in each assembly and with the lipid bilayer. Specific interaction pairs 
are considered to be relevant if the number of atomic interaction pairs, NP, is greater than 15. 
As the MPER-TMD1 structure is no longer symmetric, no residue pairs are identified with an 
average NP of more than 15 (Fig. 6A). Deconstruction of the MPER-TMD1 contact map into 
individual pairs of helices (Fig. 6B), identifies a prominent contact interface between 
monomers A and C, incorporating residue pairs W672-W680, I675-W680, W672-K683, 
L679-K683, L679-I686, L679-M687, I682-M687, I686-I693 and V689-I697 (NP > 15), with 
L679-K683 and L679-M687 being the most prominent contacts (NP > 25). This implies that 
monomers A and C shift relative to one another (region W672-V689 of A interacts with 
region W680-I697 of C) due to the increased tilt angle of helix A. On the other hand, region 
K683-I693 of monomer B interacts with region I686-R696 of A via residue pairs, K683-I686, 
M687-I686, I686-I693, M687-V689, G690-I693, I693-I693, and I693-R696 (NP > 15), with 
I686-I693 and I693-R696 being the most prominent pairs identified. Finally, no residue pairs 
are identified (with NP > 15) between monomer B and C. These results indicate that MPER-
TMD1 contains two energetically favorable dimer interfaces, between the N-terminal regions 
of helices A and C and the C-terminal regions of A and B.  
In contrast, in the MPER-TMD2 simulation, inter-helical interactions span the region between 
W678 and I697 with several residue pairs identified with NP > 15 (Fig. 6C). Residue pairs 
W678-L679, I682-K683, F685-M687, F685-I686, I686-I686, L692-I693, I693-I693, and R696-
I697 exceed this value, when averaged over the three helices. In this case, deconstruction of 
the MPER-TMD2 contact map into individual pairs of helices reveals that similar residues 
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participate in pairwise interactions (Fig. 6D) consistent with the near-symmetrical 
conformation of the trimer.  Overall, residues I686 and I693 corresponding to the a and d 
positions of the coiled-coil, are involved in 32 % and 26 % of the total number of interaction 
pairs, and thus, contribute to the stability of the trimer to the greatest extent. 
Regarding interactions with lipids, residues K668 and W680 populate the head group region 
of the upper leaflet in helix A and residues K668 and K670 in helix C of the MPER-TMD1 
simulation, whereas W672, F673 and W678 occupy this region in helix B (Fig. 7A). In the 
lower leaflet, C-terminal lysine residues inhabit the head group region in all helices, and also 
R696 in helix A, despite residing in the hydrophobic core. Critical residues that anchor the 
peptide to the hydrophobic membrane core, common to all helices, include Y681, L684, 
F685, I688, L692 and L695 (Fig. 7B). However, several differences between the helices are 
observed regarding acyl chain interactions, with W678 displaying an elevated number of 
interactions with the acyl chains in helices A and C, and W680 and M687 in helix B. 
Moreover, it’s worth noting that C-terminal residues in helix C unfold to facilitate snorkeling 
of lysines 700 to 704 and to permit accommodation of the hydrophobic residues to the 
thickness of the bilayer (Fig. 1C). Similarly, helix A unfolds to accommodate the helix to the 
thickness of the hydrophobic core, in this case between residues G694 and V698. Helix B, 
which is less tilted, spans the membrane without unfolding. In the case of the MPER-TMD2 
simulation, residues W680 and R709 in all three helices consistently populate the head 
group region of the upper and lower leaflets, respectively. Furthermore, besides the residues 
described to interact with the acyl chains in MPER-TMD1, interactions between residues 
M687, S691, I697, V698, F699, V701 and V702 and the hydrophobic core of the membrane 
were also recorded. 
3.3.4 Accessibility of the 10E8 epitope residues 
To assess accessibility of the epitope within the MPER-TMD scaffolds, the average number 
of atomic interactions of the main epitope residues, N671, W672, F673, T676, W680 and 
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K683, with other protein residues was calculated (Table 1). These residues display 
approximately 100 interactions in MPER-TMD1 helix A, mainly resulting from W672 and 
K683. In helix B, the number of interactions is at a minimum, with K683 involved in an 
average of 8 interaction pairs and no interactions recorded for the other residues. Hence, the 
10E8 epitope in helix B retains a large surface area to interact with other species. However, 
epitope residues in this helix are engaged in extensive lipid interactions (Fig. 7 and Table 2); 
W672 and F673 interact with the phospholipid head groups, and W680 and, to a lesser 
extent K683, interact with the hydrophobic core. In helix C, protein residues occlude the 
lower region of the epitope, with W680 and K683 involved in ca. 120 interaction pairs. In 
contrast, N-terminal epitope residues N671, W672 and F673 are not engaged in interactions 
with other residues or surrounding lipid molecules. Thus, the N-terminal part of helix C in 
MPER-TMD1 is exposed to the solvent and might effectively interact with the antibody.  
Conversely, epitope residues in each of the three MPER-TMD2 helices display an average 
of 60-100 interactions in total, primarily constituted of residues K683 and W672 (Table 1). 
These interactions are the consequence of the near-symmetric trimer arrangement and the 
inward-facing orientation of these residues in the observed MPER-TMD2 conformation. 
Moreover, residue W680 displays interactions with the surrounding lipid molecules, both with 
the polar head groups or the acyl chains of the lipids (Fig. 7 and Table 2). As a result, the 
epitope can be considered inaccessible to incoming antibody molecules. These observations 
support the experimentally observed deficient antigenicity of MPER-TMD2.  
3.3.5 Effect of the flanking lysines on the MPER-TMD1 model  
Finally, to determine to what extent factors conditioning accessibility of 10E8 epitope on 
MPER-TMD1, i.e., loss of symmetry and inter-helical interactions of the MPER-TMD1 trimer, 
depend on the truncation of the TMD at A700 and/or on the presence of lysine residues at 
both ends, three additional models were generated: 1) residues 671-700 without lysines 
(MPER-TMD1no-lys); 2) residues 671-700 with three lysines at the N-terminus (MPER-
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TMD1N) and 3) residues 671-700 with three lysines at the C-terminus (MPER-TMD1C). MD 
simulations were performed for 200 ns, and the last 100 ns were considered for analysis 
(Figs. 8 and S2, and Tables S1-4).  
MPER-TMD1no-lys resembles most closely the results obtained with the MPER-TMD2 
construct devoid of lysines, with a RMSD of 2.6 ± 0.1 Å (Fig. S2A) and an increased 
verticality of the helices (tilt angles between 7-20°) (Fig. S2C). In contrast, RMSD values are 
significantly higher for MPER-TMD1C (3.2 ± 0.3 Å) and especially, for MPER-TMD1N (4.7 ± 
0.2 Å), the latter displaying a similar value to that of the MPER-TMD1 construct flanked by 
lysines. Similarly, two of the three helices of either N or C lysine-flanked assemblies display 
a significant increase in their tilt angles. However, unlike MPER-TMD2, inspection of the 
number of atomic interaction pairs between adjacent helical pairs in MPER-TMD1no-lys 
suggests a loss of symmetry in the latter, displaying an extensive contact interface between 
the CA helices (Fig. S2B), where residue pairs scoring NP>15 extend the full length of the 
MPER-TMD1 peptide (Fig. 8). This situation is replicated in MPER-TMD1N, between helices 
A and B. The similarity of the evolved conformations provides evidence that truncation of the 
peptide at residue 700, destabilizes the symmetric trimer structure, preferring an assembly 
whereby two helices are closely associated, with the third attached by hydrophobic residues 
in the region between I682 and I693. Addition of lysine residues at the C-terminus in MPER-
TMD1C and in the original MPER-TMD1 assembly flanked by lysines, promotes further 
destabilization of the observed ‘dimer’ interfaces, with the maximum number of inter-helical 
interactions capped at 350 (Fig. S2B), and with fewer residue pairs scoring NP>15 (Fig. 8). 
These results imply that truncation of the TMD causes a rearrangement of the TMD structure 
favoring trimer asymmetry and a dimer interface, which is partially inhibited by including 
lysines after A700.  
When scoring interactions with lipids, a similar trend is exhibited for the three new 
simulations (Tables S1 and S2) and that of MPER-TMD1, regardless of the absence or 
presence of lysine tags, with W678 or W680 interacting with the phospholipid headgroups of 
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the upper leaflet in at least one of the monomers in each assembly and, to a lesser extent, 
with K668 and K670 (MPER-TMD1N, helix B) and W672 or F673 (MPER-TMD1C, A and B 
helices, respectively). Furthermore, residues that strongly interact with the hydrophobic core 
of the membrane are conserved in all MPER-TMD1 simulations. Thus, due to the similar 
degree of insertion into the membrane of all the models, no interactions are recorded 
between MPER-TMD1no-lys or MPER-TMD1N C-terminal residues and the phospholipid 
headgroups in the lower leaflet, as opposed to constructs bearing lysines at the C-terminus, 
which display interactions through the lysine residues.  
Finally, the average number of atomic interactions of the main epitope residues with 
adjacent helices (Table S3) and the surrounding lipids (Table S4) was calculated. In MPER-
TMD1no-lys epitope residues in each of the three helices display an average of 60-110 
interactions in total, primarily constituted of residues W672 and K683. Moreover, residue 
W680 displays extensive interactions with the surrounding lipid molecules. These results 
replicate those obtained for MPER-TMD2 and advocate that truncation to residue 700 alone 
is insufficient to expose the antibody epitope, despite destabilization of the symmetric trimer 
arrangement. In MPER-TMD1N, the epitope in helix A can be considered unavailable, with 
nearly 200 atomic interactions in the region F673 to K683. The 50-recorded interactions for 
helix B primarily originate from W672. In helix C, only 10 protein interactions are observed 
from W680 and K683, which also dominate lipid interactions throughout. Similar to the 
MPER-TMD1 model flanked by lysines at both ends, these results reveal a single helix (C) 
where the N-terminal epitope residues (N671, W672 and F673) are exposed to solvent, 
engaging in minimal protein (1) and lipid (32) and might effectively interact with the antibody. 
Finally, in MPER-TMDC, helix B displays the minimum number of protein (14) and lipid (42) 
interactions with such residues. These results suggest the addition of lysine residues to the 
N-terminus is an effective strategy for epitope exposure. 
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4- Discussion 
In the present work, we have analyzed the effect of HIV-1 gp41 TM domain on the exposure 
of the MPER epitope at the surface of lipid bilayers. With this aim, we designed two MPER-
TMD sequences based on previously reported mutagenesis studies of the TMD [9]: MPER-
TMD1, in which the TMD was truncated at A700, and MPER-TMD2, which spans the full 
TMD up to R709 (Fig. 1). Given the critical role of the lipid membrane in various stages of 
the HIV virus cycle [56] and particularly, in the recognition of their epitopes by the antibodies 
4E10 and 10E8 [30, 48, 57], it has been argued that not only Env structure but also its 
membrane environment should be preserved in the development of vaccines that aim to 
elicit anti-MPER antibodies targeting its C-terminal region (i.e., 4E10/10E8) [19, 58]. 
Therefore, MPER-TMD1 and MPER-TMD2 were formulated in HIV-1 like cholesterol-
enriched liposomal-vaccines [33] and immunochemical assays were performed to test the 
antigenicity of both candidates. The results revealed that MPER-TMD1, but not MPER-
TMD2, was capable of specific and efficient antibody recognition by anti-MPER bnAbs (Figs. 
2, 3 and S1). Moreover, MPER-TMD1 was shown to migrate as dimers under denaturing 
conditions. Consistent with this behavior, reported mutagenesis studies of the TMD showed 
that truncation of residues 705 to 716 induced partial destabilization of the trimer [13]. 
Moreover, analyses of the NMR spectra of a gp41 construct terminating at residue 705 
showed conformational flexibility in the CHR-MPER-TM region of gp41, pointing to the 
potential of this region to display conformations other than a stable trimer during the fusion 
process [59]. In contrast, our experimental data indicated that the longer MPER-TMD2 was 
reportedly more stable, demonstrated by the presence of dimers and trimers following 
denaturing treatment (Figs. 2, 3 and S1). This assorted dimer and trimer migration pattern 
was also reported for a similar peptide containing the full-length MPER (residues 661-708 
plus four C-terminal lysines) incorporated into DMPC nanodiscs [29]. These results suggest 
that the TM domain is instrumental in the trimerization process, whereas the MPER domain 
does not play a significant role. However, opposing our results, high affinity recognition of 
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bnAb 4E10 to that peptide was reported [29]. Besides N-terminal elongation and C-terminal 
addition of lysines, the physical and chemical properties of the selected lipids utilized in both 
studies were also dissimilar. The thickness of a DMPC bilayer is reported to be of around 
35-37 Å [60, 61], significantly thinner than that of cholesterol-enriched phospholipid bilayers 
[61] such as the viral envelope [33, 62]. Cholesterol augments membrane physical 
properties such as rigidity and thickness, thereby affecting TMD helix accommodation within 
the lipid bilayer [63], and conceivably, modulating the MPER-scaffolding capacity, i.e., the 
antigenicity of the MPER-TMD constructs. This might account for the reported differences 
observed between the two studies and highlights the importance of the membrane 
composition in the design of liposomal vaccines targeting the 10E8 epitope.  
The computational analysis of the candidate liposomal vaccines confirms the above 
experimental observations and reveals the molecular mechanism underlying efficient epitope 
exposure in the MPER-TMD1 scaffold. Overall, two distinctive conformations of the MPER-
TMD assemblies were observed. Whereas MPER-TMD2 closely resembles the three-fold 
assembly observed in the NMR structure of the HIV-1 TMD [13], the close association of the 
transmembrane helices is noticeably perturbed in all MPER-TMD1-based models resulting in 
an asymmetric assembly (Figs. 4-6, 8 and S2). Therefore, destabilization of the MPER-
TMD1 trimer, can be attributed to truncation of the TMD following A700 to some extent.  It 
should be emphasized that the residues involved in inter-helical interactions in the MPER-
TMD2 trimer are all present in MPER-TMD1 assemblies; thus, it is primarily environmental 
interactions that influence the dynamics of the MPER-TMD derived scaffolds. Substantial 
interactions between V701 and L702 and the acyl tails, and between R709 and the 
phospholipid head groups, observed in MPER-TMD2 (Fig. 7) are lost upon truncation; thus, 
the observed reorientation of the helices to an asymmetric arrangement in MPER-TMD1-
based assemblies can be attributed to the absence of lipid interactions with such residues. 
We speculate that, as previously demonstrated [9], R709 is particularly crucial for membrane 
anchoring, as truncation of the region following this residue results in a stable assembly, 
profoundly similar to the initial construct.  In addition, the resulting conformation of MPER-
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TMD1 trimers bearing lysines accommodates for the positively charged lysine residues, 
which are predominantly excluded from the membrane hydrophobic core contributing to the 
perturbed conformation of the MPER-TMD1 trimer, the underlying α-helices and the bilayer. 
These effects were not detected in the MPER-TMD2 simulation, in which sequence 
composition, length and tilt angles are more compatible with the hydrophobic core 
dimensions of this bilayer. Moreover, MPER-TMD1 models devoid of lysines or with lysines 
at the N-terminus reveal a prominent new dimer interface indicating that TMD helices have 
the potential to adopt multiple conformations. It is tempting to speculate that in the context of 
the whole protein and due to the dynamic nature of Env [4, 64, 65] the TMD might suffer 
conformational changes, such as reorientations, variations in the tilt angles or dissociation 
events, which might perturb the viral envelope priming it for fusion with the cellular 
membrane, or alternatively, which might permit establishing interactions with TMD helices 
from adjacent trimers at crucial moments of the fusion cycle.  
The specific molecular interactions of the residues within the epitope region might be used to 
rationalize the distinct antigenicity pattern of the MPER-TMD scaffolds (Tables 1, 2, and S1 
and S2). Main epitope residues in MPER-TMD2 and in MPER-TMD1no-lys face the core of the 
trimer with crucial residues W672 and K683 engaged in inter-helix contacts and with W680 
interacting with the lipid molecules. Although residue W680 is not essential for the binding of 
4E10 and 10E8 to their epitopes in solution it is important for the viral-neutralization function 
of these antibodies [24, 66-68]. Moreover, it was shown to modulate the immunogenicity of 
MPER-derived peptides by shifting the specificity of the immune response towards the N-
terminus when W680 was embedded in the membrane [69]. Thus, in both models, the 
MPER epitope faces the interior of the trimer in a conformation that might hinder antibody 
recognition at membrane surfaces. These observations might have implications regarding 
the structure of the TMD in the context of the pre-fusion conformation of the native Env. 
Since the conformation of the MPER-TMD2 scaffold greatly resembles the original structure 
solved by NMR in bicelles [13], we hypothesize that such structure would not represent the 
neutralization competent structure recognized by 10E8. Consequently, the NMR structure is 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 23 
also likely to differ from the pre-fusion structure of the native Env which was recently solved 
by cryo-EM bound to two molecules of bnAb 10E8 [4]. In the case of the MPER-TMD1 
construct flanked by lysines, epitope residues within each helix display a distinct interaction 
pattern. Epitope residues in helix B are not engaged in inter-helix interactions in helix B but 
are buried in the membrane, and thus, inaccessible to the antibodies. In contrast, epitope 
residues in helices A and C were not found to interact with lipids. However, similarly to 
MPER-TMD2, W672 and K683 in helix A are engaged in inter-helix interactions possibly 
precluding antibody recognition of the epitope. Finally, although C-terminal epitope residues 
W680 and K683 are interacting with residues in other helices, N-terminal epitope residues 
N671, W672 and F673 are fully exposed. A similar pattern is recorded for helix C in MPER-
TMD1N. Although both protein and lipid molecules will likely be perturbed to some extent by 
approach of the antibody, the data presented herein provide evidence that the epitope 
region undergoes conformational differences depending on the protein scaffold used to 
present the epitope, being considerably more likely that the antibody will recognize MPER-
TMD1 or MPER-TMD1N than MPER-TMD2, MPER-TMD1no-lys or MPER-TMD1C, where the 
epitope is either stably embedded in the trimer core or interacting with lipid molecules. We 
hypothesize that antibody recognition of the exposed epitope and subsequent binding to 
these peptides would require a two-step binding mechanism, in which the antibody would 
first approach the MPER and bind to the N-terminal residues. This interaction would 
conceivably alter the pre-existing inter-helix interactions at the C-terminal part of the epitope 
and the rest of the paratope could then be effectively accommodated.  
Overall, these results suggest that inclusion of particular attributes that destabilize the trimer, 
i.e., truncation of the TMD, and expose the epitope, i.e., addition of N-terminal lysines, would 
likely aid the optimization of MPER-TMD derived peptides in the context of vaccine design. 
In the context of the virus, the intrinsic dynamics of Env [4] might transiently extract and 
expose the MPER leading to the engagement of B-cell receptors, but in the absence of 
these forces, in the context of a minimal immunogen, MPER should be readily exposed to 
the immune system. In this regard, extensive mutagenesis studies, performed by Dev et al., 
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examining the antigenic structure of the Env ectodomain [13] showed that even the most 
simple mutations in the TMD region (F685A, I686A, G690A, L692A, G694V, L695A, I697A) 
modulated the antigenic surface of Env and specifically, increased viral sensitivity to 10E8. 
Residues, F685, I686, L692 and I697 are involved in crucial inter-helical interactions in the 
MPER-TMD2 trimer only, thus it can be inferred that mutation of these residues might 
destabilize the canonical structure, and potentially lead to the exposure of expose the 10E8 
epitope.  
All in all, the immunochemical assays and in-depth MD analyses reported herein suggest 
that the structure-based design of effective liposomal vaccines based on the MPER-TMD 
might require a rational mutation strategy of the TMD along with a systematic analysis of the 
lipid bilayer, to achieve efficient exposure of the MPER epitope at the membrane surface. 
Overall, this study advances our understanding of the requirements that must be met by a 
liposome-based peptide-vaccine targeting this critical antigenic site on Env. 
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Figure Captions: 
Figure 1. Description and structure of the HIV-1 gp41 MPER-TMD sequences used in 
the present study. A) Weblogo representation of MPER-TMD sequence variability of all 
HIV-1/SIVcpz subtype genomes (filtered web, 5132 sequences) available at the LANL HIV 
Sequence Database (http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). 
Gp41 amino acids 671 to 709 are shown (HXBc2 prototypic isolate numbering) color-coded 
according to their chemical properties (polar - green, neutral - purple, basic - blue, acidic - 
red and hydrophobic - black) and lines below the logo span the sequences covered by the 
peptides used in this study. Lines above the logo depict the MPER, N-TMD and C-TMD 
domains of gp41, and the full epitope of 10E8 antibody is highlighted. The gp41 ectodomain 
(PDB ID: 5FUU) is shown as ribbons (dark grey). B) Secondary structure of MPER-TM 
domain derived synthetic peptides. Circular dichroism spectra of MPER-TMD1 and MPER-
TMD2 peptides in the low polarity medium provided by 25 % HFIP (left and right panels, 
respectively). 
 
Figure 2: Association of 10E8 Fab and its mutant version to MPER-TMD1 and MPER-
TMD2 reconstituted into cholesterol-enriched vesicles proved by ultracentrifugation in 
a sucrose gradient. POPC:Chol:PA 10:11:1 (mol:mol) liposomes containing 0.5 % of Rho-
PE were reconstituted without peptide (A) or with 30 M  MPER-TMD1 (B) or MPER-TMD2 
(C) at a 1:50 peptide-to-lipid molar ratio and were incubated for 15 min at RT and under 
constant stirring (800 rpm) with 0.07 mg/mL of 10E8 or 10E8 W100bD Fabs (from left to 
right). The samples were then subjected to ultracentrifugation in a sucrose gradient and 
harvested in 5 fractions. Peptides (10 kDa bands) and bound or unbound Fabs (25 kDa 
bands) were size-separated by tricine-PAGE-SDS and proved by Western blot. Effective 
flotation of the vesicles was monitored following the fluorescence emission of the rhodamine 
probe included in the liposomes as depicted by the spectra below each panel.    
 
Figure 3. Specific binding of 10E8 Fab to MPER-TMD1 and MPER-TMD2 reconstituted 
into cholesterol-enriched vesicles or in solution proved by photo-cross-linking. 0.07 
mg/mL of 10E8 W100bHCpBPA Fab was incubated alone, with the peptides in solution or 
with the peptides reconstituted into membranes, for 15 min at RT and under constant stirring 
(800 rpm), followed by irradiation with UV-light or no treatment. Peptides, heavy and light 
chains of the Fabs, and photo-cross-linked Fab-peptide adducts were detected by 
Coomassie-blue staining. Pink bands at the bottom of the gel revealed the presence of 
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Rhodamine-labeled liposomes in the samples.  The arrow points to the position of the photo-
cross-linked product. 
 
Figure 4: Overview of the MPER-TM domain simulations. Snapshots of the MD 
simulations of MPER-TMD1 (left) and MPER-TMD2 (right) models (A) at time 0 ns (side 
view) and (B) at time 200 ns (side and top views). The structural models were constructed 
with UCSF Chimera using 5GHW and 5JNY structures deposited in the PDB. Helices A, B 
and C are colored in purple, pink and orange, respectively. Main 10E8 epitope residues 
(671NWF--T---W--K683) are colored lighter in each helix and K683 of one monomer is shown 
as spheres to mark the predicted starting point for the TMD. The arrows depict the average 
thickness of the bilayer, which was calculated as the distance between the projected mass 
distribution of the phosphorous atoms in the upper and lower leaflets, using the 
MEMPPLUGIN of VMD. 
 
Figure 5: Overall stability of the MPER-TM domain simulations. A) RMSD of the MPER-
TM domain residues 671 to 690 in the MPER-TMD1 (red) and MPER-TMD2 (green) models 
over the course of the simulations. B) Average number of interaction pairs between subunit 
pairs in the MPER-TMD1 (red), MPER-TMD2 (green) and the initial situation (yellow outline) 
averaged from frames at 50 ps intervals. An interaction pair is counted if the distance 
between two atoms is less than 4 Å. C) Tilt angle () of individual helices (residues 671 to 
690) with respect to the bilayer normal over the course of the simulations. Each helix is 
displayed in a different color (A-C helices, purple, pink and orange, respectively). The inset 
data represent the average tilt angle of each individual helix during the final 100 ns of the 
simulation. 
 
Figure 6. Inter-helix interactions between protein residues in the MPER-TMD 
simulations. A) Number of interaction pairs between specific residues in the MPER-TMD1 
simulation averaged over the three subunits and the trajectory. B) Deconstruction of the 
MPER-TMD1 residue contact map into individual helices. C) Number of interaction pairs 
between specific residues in the MPER-TMD2 simulation averaged over the three subunits 
and the trajectory. D) Deconstruction of the MPER-TMD2 residue contact map into individual 
helices. 
 
Figure 7: Map of interactions between specific residues in the MPER-TMD simulations 
and the lipid membrane. Number of interaction pairs between residues in individual helices 
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and (A) lipid head group atoms and (B) lipid tail atoms. The y-axis denotes the simulation 
and subunit. It is worth noting that not all residues defined on the x-axis are present in all 
peptides (grey areas), and specifically residues 700-704 are lysine residues in MPER-TMD1. 
The grey box and arrows highlight the 10E8 epitope region and the most important residues.  
 
Figure 8. Inter-helix interactions between protein residues in the MPER-TMD 
simulations. Number of interaction pairs between specific residues of individual helices in 
the A) MPER-TMD1no-lys simulation B) MPER-TMD1C simulation and C) MPER-TMD1N 
simulation.  
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Table 1. Average number of interactions of 10E8 epitope residues. 
 
 
 
  
Simulation Helix 
Average Number of Inter-Helical Interactions 
N671 W672 F673 T676 W680 K683 Total 
MPER-
TMD1 
A 0 61 0 4 8 33 106 
B 0 0 0 0 0 8 8 
C 1 0 0 11 64 57 131 
MPER-
TMD2 
A 9 41 1 6 2 35 103 
B 6 42 0 7 3 39 97 
C 0 28 0 0 1 32 61 
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Table 2. Average number of lipid interactions of 10E8 epitope residues 
 
  
Simulation Helix 
Average Number of Lipid Interactions  
N671 W672 F673 T676 W680 K683 Total 
LIPID+ 
PROTEIN 
MPER-
TMD1 
A 10 9 16 1 69 24 129 235 
B 2 41 50 25 117 48 283 291 
C 15 13 3 4 38 4 77 208 
MPER-
TMD2 
A 0 0 7 2 95 33 137 240 
B 0 0 6 2 94 41 143 240 
C 0 1 11 6 92 44 154 215 
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Highlights 
 
- 10E8 antibody neutralizes most HIV-1 strains; thus, it is target of vaccine design.  
- 10E8 epitope exposure is analyzed in membrane-reconstituted MPER-TMD peptides. 
- Immunochemical assays and Molecular Dynamics Simulation analyses are combined. 
- TMD truncation at A700 destabilizes the reported trimer structure.  
- A rational mutagenesis strategy is proposed to improve 10E8 epitope exposure.  
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